Komori
Terumo (4543) · RiskFirst stated

Changes in Product and Treatment Evaluation Driven by the Discovery of New Evidence in Medicine

First written in FY2021. . Latest entry: FY2021.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Risk of changes in product and treatment assessments due to new medical evidenceA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2021First statedAnnual report

    「However, if the efficacy expected of a product is not demonstrated, or new defects or side effects are discovered in a treatment previously considered effective, this may affect the Company's business results and financial condition.」

    Disclosed the risk that evaluations of product efficacy and safety may change based on research findings and clinical data as a new standalone item.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Terumo yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Changes in Product and Treatment Evaluation Driven by the Discovery of New Evidence in Medicine | TERUMO CORPORATION (4543) | Komori